FBXL4: The Potential Drug Target and Biomarker for Leucine-Rich Repeat Proteins

Target Name: FBXL4

NCBI ID: G26235

FBXL4

FBXL4: The Potential Drug Target and Biomarker for Leucine-Rich Repeat Proteins

Leucine-rich repeat (LRR) proteins are a family of transmembrane proteins that play a crucial role in various cellular processes. One of the most well-known LRRs is Facebook X Protein (FBXP), also known as FBXL4. FBXP is a protein that contains a LRR and is involved in various cellular processes, including cell signaling, DNA replication, and protein stability. FBXP has also been shown to be a potential drug target and biomarker.

FBXL4: Structure and Function

FBXP has a molecular weight of approximately 41 kDa and consists of a 166 amino acid residue. It has a unique structure that consists of a catalytic center, a transmembrane region, and an N-terminus. The catalytic center is located at the N-terminus of the protein and consists of a Rossmann-fold, which is a conserved structural motif that is involved in protein-protein interactions. The transmembrane region is located between the catalytic center and the N-terminus and consists of a series of LRRs and a hydrophobic region.

FBXP functions as a protein that can interact with various cellular components, including DNA, RNA, and proteins. One of the most well-known functions of FBXP is its role in DNA replication. FBXP has been shown to play a crucial role in regulating the replication of DNA in various cell types, including HeLa cells and cancer cells.

In addition to its role in DNA replication, FBXP has also been shown to be involved in cell signaling. FBXP has been shown to interact with various signaling proteins, including T-cell factor (TGF-β), which is a cytokine that plays a crucial role in cell signaling. FBXP has also been shown to regulate the activity of the protein kinase B, which is involved in cell signaling.

FBXP has also been shown to be involved in protein stability. FBXP has been shown to interact with various proteins, including the protein ubiquitin, which is involved in protein degradation. This interaction between FBXP and ubiquitin suggests that FBXP may play a role in regulating protein stability.

Drug Targeting

FBXP has been shown to be a potential drug target due to its unique structure and various functions. One of the most promising strategies for targeting FBXP is to use small molecules that can modulate its activity.

One of the most well-known small molecules that can modulate FBXP's activity is the drugletectin, which is a peptide that consists of the N-terminal region of FBXP. The N-terminal region of FBXP contains a series of LRRs that are involved in protein-protein interactions and may be targeted by small molecules. The use of drugletectin has been shown to be effective in modulating FBXP's activity, including its ability to interact with DNA and RNA.

Another small molecule that may be able to modulate FBXP's activity is the drug gefitinib, which is a inhibitor of the protein tyrosine kinase (PTK). PTK is a protein that is involved in cell signaling and is a potential target for many diseases, including cancer. The use of gefitinib has been shown to be effective in modulating FBXP's activity, including its ability to interact with DNA and RNA.

Biomarker

FBXP has also been shown to be a potential biomarker for various diseases, including cancer. One of the most promising strategies for using FBXP as a biomarker is to use its ability to interact with DNA and RNA as a diagnostic tool. For example, the use of FBXP-based assays has been shown to be effective in detecting various types of cancer, including breast

Protein Name: F-box And Leucine Rich Repeat Protein 4

The "FBXL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets